Description
LAG-3 / NFAT Reporter - Jurkat Recombinant Cell Line | 71278 | Gentaur US, UK & Europe Disrtribition
Category: Immunotherapy/Cell Line
Application: Screen for activators or inhibitors of LAG-3 signaling in a cellular context and characterize the biological activity of LAG-3 and its interactions with ligands
Background: Lymphocyte-activation gene 3 (LAG-3, CD223) is a cell surface protein that belongs to immunoglobulin (Ig) superfamily. LAG-3 is expressed on activated T cells, natural killer cells, B cells, and plasmacytoid dendritic cells. Its main ligand is MHC class II, to which it binds with higher affinity than CD4. It negatively regulates cellular proliferation, activation, and homeostasis of T cells, in a similar fashion to CTLA-4 and PD-1, and has been reported to play a role in Treg suppressive function. A number of LAG-3 antibodies are in preclinical development for treatments for cancer and autoimmune disorders. LAG-3 may be a better immune checkpoint inhibitor target than CTLA-4 or PD-1 since antibodies to these two checkpoints are only activating effector T cells, and not inhibiting Treg activity where an antagonist LAG-3 antibody can both activate effector T cells (by downregulating the LAG-3 inhibiting signal) and inhibit induced (i.e. antigen-specific) Treg suppressive activity.
Description: Recombinant Jurkat T cell expressing firefly luciferase gene under the control of NFAT response elements with constitutive expression of human LAG-3 (lymphocyte-activation gene 3, CD223, GenBank Accession # NM_002286).
Product Type: Cell Line
Shippement Condition: -80°C
